Please use this identifier to cite or link to this item:
Title: Resveratrol derivative, trans-3,5,4 '-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of vegfr2 and cell-cycle modulation
Authors: Alex, D
Leong, EC
Zhang, ZJ
Yan, GTH
Cheng, SH
Leong, CW
Li, ZH
Lam, KH
Chan, SW
Lee, SMY
Keywords: 3,5,4 '-Trimethoxystilbene
Cell cycle
Issue Date: 2010
Publisher: Wiley-Liss
Source: Journal of cellular biochemistry, 2010, v. 109, no. 2, p. 339-346 How to cite?
Journal: Journal of Cellular Biochemistry 
Abstract: Angiogenesis plays an important role in the development of neoplastic diseases such as cancer. Resveratrol and its derivatives exert antiangiogenic effects, but the mechanisms of their actions remain unclear. The aim of this study was to evaluate the antiangiogenic activity of resveratrol and its derivative trans-3,5,4'-trimethoxystilbene in vitro using human umbilical vein endothelial cells (HUVECS) and in vivo using transgenic zebrafish, and to clarify their mechanisms Of action in zebrafish by gene expression analysis of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/KDR) and cell-cycle analysis. trans-3,5,4'-Trimethoxystilbene showed significantly more potent antiangiogenic activity than that of resveratrol in both assays. In zebrafish, trans-3-5-4'-trimethoxystilbene caused intersegmental vessel regression and downregulated VEGFR2 mRNA expression. Trans-3,5,4'-trimethoxystilbene also induced G2/M cell-cycle arrest, most specifically in endothelial cells of zebrafish embryos. We propose that the antiangiogenic and vascular-targeting activities of trans-3,5,4'-trimethoxystilbene result front the downregulation of VEGFR2 expression and cell-cycle arrest at G2/M phase.
ISSN: 0730-2312
DOI: 10.1002/jcb.22405
Appears in Collections:Journal/Magazine Article

View full-text via PolyU eLinks SFX Query
Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.